MultIceNtre non-intERVentional study for efficacy,safety evaluation of BREZTRI in pts with COPD in RussiA

Trial Identifier:	D5980R00097
Sponsor:	AstraZeneca
Start Date:	December 2023
Primary Completion Date:	December 2024
Study Completion Date:	December 2024
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Russia	Saint-Petersburg, Russia

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.